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ABSTRACT 
Objective: We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on 
the medical management of paediatric Crohn’s disease [CD].  
Methods: We formed 10 working groups and formulated 17 PICO-structured clinical questions 
[Patients, Intervention, Comparator, and Outcome]. A systematic literature search from 1 January 
1991 to 19 March 2019 was conducted by a medical librarian using MEDLINE, EMBASE, and Cochrane 
Central databases. A shortlist of 30 provisional statements were further refined during a consensus 
meeting in Barcelona in October 2019 and subjected to a vote. In total 22 statements reached  80% 
agreement and were retained.  
Results: We established that it was key to identify patients at high risk of a complicated disease 
course at the earliest opportunity to reduce bowel damage. Patients with perianal disease, 
stricturing or penetrating behaviour, or severe growth retardation should be considered for up-front 
anti-TNF agents in combination with an immunomodulator. Therapeutic drug monitoring to guide 
treatment changes is recommended over empirically escalating anti-TNF dose or switching therapies. 
Patients with low-risk luminal CD should be induced with exclusive enteral nutrition [EEN], or with 
corticosteroids when EEN is not an option, and require immunomodulator-based maintenance 
therapy. Favourable outcomes rely on close monitoring of treatment response, with timely 
adjustments in therapy when treatment targets are not met. Serial faecal calprotectin measurements 
or small bowel imaging [ultrasound or magnetic resonance enterography] are more reliable markers 
of treatment response than clinical scores alone.  
Conclusion: We present state-of-the-art guidance on the medical treatment and long-term 
management of children and adolescents with CD.  
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1. INTRODUCTION 
Approximately 10% of patients with Crohn’s disease [CD] are diagnosed before their seventeenth 
birthday.1 The past decade has seen significant advances in the care of children with CD. With an 
expanding therapeutic armamentarium, there has been a shift of therapeutic goals from symptom 
control alone towards mucosal and transmural healing with consequent reduction of bowel damage.  
The objective of this evidence-based guideline update by the European Crohn’s and Colitis 
Organisation [ECCO] and the Paediatric IBD Porto group of European Society of Paediatric 
Gastroenterology, Hepatology and Nutrition [ESPGHAN] was to review existing data on the efficacy 
of available medical therapies and provide therapeutic algorithms for paediatric practice, including 
advice on how to monitor response to treatment. This guideline replaces the first ECCO-ESPGHAN 
guideline published in April 2014.2  
 
2. METHODOLOGY 
We followed the ECCO standard operating procedures for guideline development. After an open call 
for interest, ECCO and ESPGHAN selected a panel of 25 paediatric IBD experts who were supported 
by a medical librarian and a webmaster for the online guideline platform. A core group of six 
paediatric IBD opinion leaders identified 10 domains within the medical treatment of CD that should 
be addressed by this guideline. Ten working groups were then formed. All panellists were assigned to 
one or two working groups, coordinated by working group leaders, all under the supervision of the 
two guideline coordinators [PFvR, FMR]. The working groups formulated a series of specific questions 
using the PICO format [Population, Intervention, Comparator, Outcomes] that were deemed to be 
clinically relevant [Supplementary file 1]. A systematic search of the literature relevant to the clinical 
questions from 1 January 1991 to 19 March 2019 was then conducted by a medical librarian using 
MEDLINE, EMBASE, and Cochrane Central databases. Focused top-up searches were performed until 
1 March 2020 to provide evidence as up to date as possible. Two working group members 
independently assessed the relevance of each abstract against predefined inclusion criteria. Eligible 
publications were randomised controlled trials [RCTs], cohort studies, and case-control studies that 
followed patients with luminal or perianal fistulising CD. Publications presented only in abstract form 
were excluded. In the case of positive concordance between physician screeners, the full text 
manuscript of each eligible publication was obtained. Disagreements were resolved by discussion. 
The criteria of the Oxford Centre for Evidence-Based Medicine were used to assess the level of 
evidence [https://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf]. 
The evidence was downgraded if the publication did not address the PICO question directly in terms 
of patients, interventions, and outcomes. An exception to this rule was the situation where 
observational paediatric studies supported the findings of adult randomised trials. In this case, the 
evidence was not downgraded. 
Each working group reviewed the selected full-text manuscripts, created evidence tables, and 
generated provisional guideline statements. The provisional statements and the supporting evidence 
tables were then submitted to an online platform. Using a Delphi consensus process, two online 
voting rounds were conducted to shortlist the provisional statements that were deemed to be of 
clinical importance for the medical treatment of CD. The first round involved all guideline panellists, 
and for the second voting round all national representatives of ECCO and an international sounding 
board [applicants who showed an interest in being part of the panel, but were not selected for this 
position] were also invited to vote. Thirty provisional statements emerged from this iterative process 
and were discussed among panellists during a consensus meeting in Barcelona in October 2019. 
Some statements were further refined during this meeting and then subjected to a vote. The 
statement was considered as final when at least 80% agreement was reached during voting. Eight 
provisional statements were ultimately rejected with the remaining 22 statements contained in this 
guideline. Each statement is framed and followed by a discussion of the evidence. Practical guidance 
sections complement the evidence by providing additional information not covered by the 
statements. Summary flowcharts of medical management and drug monitoring are shown in Figures 
1 and 2. 
 
3. KEY POINTS IN THE MEDICAL TREATMENT OF PAEDIATRIC CD 
There is increasing evidence that the treatment plan for a paediatric patient with CD should be 
individualised. The plan should consider factors such as age, disease location, disease behaviour, 
presence of growth delay, potential side effects of medications and quality-of-life. A key point in 
designing an optimal treatment plan is the identification of patients at high risk of a complicated 
disease course, with the overall aim to obtain rapid control of inflammation to reduce long-term 
bowel damage. The previous paediatric CD guidelines introduced the notion of predictors of poor 
outcome [POPOs] that were mainly expert-driven.2 Since then, some of the initially proposed POPOs 
have been validated, such as disease behaviour [B2, stricturing disease; B3, penetrating disease; p, 
perianal involvement] or non-response to adequate induction therapy [see section 4]. 
 
4. RISK STRATIFICATION OF PATIENTS 
ECCO-ESPGHAN statement 1  
Patients with newly diagnosed Crohn’s disease [CD] who do not achieve clinical and biochemical 
remission after induction therapy are at risk of a more complicated disease course. 
LoE: 3 | Agreement: 92% 
 
Evidence 
Few studies have adequately addressed the issue of predicting disease outcomes in patients with 
paediatric-onset CD at diagnosis. Table 1 presents predictors for poor outcome, defined as either the 
early need for surgery or risk for rapid progression of bowel damage. While these predictors should 
be considered when choosing the appropriate induction therapy, it should be noted that these 
features are not consistently recognised across all studies.  
Several observational studies following newly diagnosed paediatric patients with CD have 
consistently shown that failure to reach clinical and biochemical remission after induction therapy is 
a predictor for poor outcome. The GROWTH CD study, a multicentre study with 222 treatment-naïve 
paediatric CD patients followed for 52 weeks, demonstrated that patients with Paediatric Crohn’s 
Disease Activity Index [PCDAI] > 5 [p = 0.012], C-reactive protein [CRP] > 20 mg/L [p = 0.019], and 
faecal calprotectin > 400 µg/g [p = 0.001] at week 12 after starting induction therapy were at higher 
risk of relapse at the end of the observation period.3 A subset of patients from the same cohort were 
followed for 104 weeks to evaluate predictors for early surgery. Again, active disease at week 12 
appeared to be a risk factor, as well as stricturing [B2] disease at diagnosis.4 Approximately 26% of 
children presenting with stricturing disease at diagnosis required early surgery in the first two years 
after diagnosis compared with 8% of patients without stricturing disease [p < 0.001]. Additionally, a 
Dutch cohort of new-onset CD showed that achieving low levels of faecal calprotectin [i.e. < 250 
µg/g] within the first 12 weeks after induction with corticosteroids or exclusive enteral nutrition 
[EEN] was associated with a favourable disease course in the first year compared to higher 
calprotectin concentrations.5  
Data from the RISK study6 suggested that early anti-tumour necrosis factor [TNF] treatment may 
prevent progression to penetrating [B3] disease but does not have added value in preventing 
stricturing complications. Nonetheless, the number of patients developing the B3 phenotype was 
small, indicating a high Number Needed to Treat value. A pro-fibrotic signature detected with RNA 
sequencing of ileal biopsies taken during diagnostic colonoscopy predicted future stricturing 
complications with a sensitivity of 69% and a specificity of 71%. Another potentially useful predictor 
for stricturing and penetrating disease is presence of antibodies against one or more microbial 
antigens, including Escherichia coli outer membrane porin C [OmpC], Saccharomyces cerevisiae 
[ASCA], and antiflagellin [CBir1]. However, the results of these studies were heterogeneous.7-10 
 
5. TREATMENT TARGETS AND MONITORING RESPONSE 
Achieving endoscopic or mucosal healing [MH] in response to induction therapy is associated with 
favourable long-term outcomes.11 Endoscopic response is commonly defined by a decrease in Simple 
Endoscopic Score for Crohn’s Disease [SES-CD] or Crohn’s Disease Endoscopic Index of severity 
[CDEIS] of at least 50% from baseline.12,13 MH is usually defined as the absence of macroscopic 
inflammation or a SES-CD < 3 points. Normal histology has been gaining increasing attention as a 
possible treatment target,14 but there is no evidence that histological remission is superior to MH in 
achieving long-term clinically important outcomes. Moreover, there are 14 different numerical 
histological indices in CD and there is no consensus on how to standardise the assessment. Thus, 
while histological remission is considered a ‘deeper’ remission than merely mucosal healing, it is 
currently still controversial as a treatment target in CD. 
 
5.1 Faecal calprotectin 
ECCO-ESPGHAN statement 2  
In patients with luminal CD following induction therapy, a decrease of faecal calprotectin in the 
context of clinical improvement can be used as a marker of treatment response.  
LoE: 3 | Agreement: 100% 
 
Evidence  
There is no evidence-based consensus of when best to re-evaluate disease activity after initiation of 
induction therapy, however repeat endoscopies to evaluate resolution of inflammation is 
impractical. There is an increasing demand to replace invasive procedures with surrogate non-
invasive markers. High-quality evidence for serial measurement of faecal calprotectin as a non-
invasive diagnostic strategy to determine resolution of inflammation comes from adult studies.15-18 In 
these studies, stool testing and ileocolonoscopy were performed simultaneously to evaluate success 
of induction therapy. Low levels of faecal calprotectin [below 150 to 250 g/g] corresponded well 
with endoscopic remission, while a failure to reach these levels often reflected ongoing intestinal 
inflammation. Several observational paediatric studies support these findings.5,19-23 In all studies, 
calprotectin values were longitudinally tracked in children following induction therapy. In one study, 
treatment success was predefined as a calprotectin result < 250 g/g in combination with absence of 
symptoms.5 Patients who achieved this target within 12 weeks had a higher probability of sustained 
remission during the first year. The other five paediatric studies did not define a target range, but 
interpreted a falling trend in calprotectin combined with a reduction of symptoms as a proxy marker 
for treatment success.19-23  
Practical guidance 
There is no linear correlation between calprotectin levels and the severity or extent of mucosal 
inflammation. Although a decrease of calprotectin during induction therapy [e.g., from 2000 to 1000 
g/g] may be statistically significant, the latter result is still indicative of active disease. A decrease of 
calprotectin within the high range should therefore not be considered a true treatment response. On 
the other hand, a decrease of faecal calprotectin to < 250 g/g [which is the upper limit of the target 
range] could be considered a reliable indicator of treatment success. The closer the calprotectin 
value gets to 50 g/g, the higher the likelihood for complete endoscopic healing.  
From birth, normal calprotectin levels exhibit a downward trend with increasing age to reach ‘adult’ 
levels around the age of 5 years.24,25 Other issues around the use of faecal calprotectin for disease 
monitoring include the lack of agreement between different test kits and limited protein stability at 
room temperature.26,27 Currently, the best advisable standard for preanalytical calprotectin handling 
is refrigeration of the filled stool container until delivery to the laboratory.27 The diagnostic gain of 
measuring calprotectin in patients with inflammation localised to the colon is well recognised, but 
the marker was thought to be less sensitive in isolated small-bowel disease. A meta-analysis 
addressing adult patients with active small-bowel CD seen on capsule endoscopy demonstrated that 
the diagnostic accuracy of faecal calprotectin is also meaningful for detection of inflammation in the 
small bowel.28  
  
ECCO-ESPGHAN statement 3  
In patients with luminal CD in clinical remission, a significant rise of faecal calprotectin should trigger 
further investigations and consideration of treatment escalation.  
LoE: 3 | Agreement: 92% 
 
Evidence  
The utility of periodic calprotectin measurements in children with inactive CD was recently evaluated 
in two prospective, single-centre cohort studies. In the first study of children receiving infliximab 
maintenance therapy, a calprotectin level > 250 μg/g measured in stool obtained prior to each 
infusion was a reliable predictor of clinical relapse in the next 3 months.29 In the other study, children 
with new-onset luminal CD were followed over time with periodic measurements of calprotectin.5 
Patients in clinical remission with an upward trend of calprotectin crossing the 250 μg/g margin were 
considered to have recurrence of disease activity and had a treatment intensification. Time-to-
recurrence, defined as the time from the first calprotectin measurement below 250 μg/g until 
treatment intensification, was longer in children in whom initial induction treatment had been 
successful within 12 weeks.  
In the multicenter ImageKids study, 151 children with new-onset or established CD underwent 
magnetic resonance enterography [MRE], ileocolonoscopy, and faecal calprotectin measurement. 
The best suitable calprotectin threshold to predict mucosal healing was 300 μg/g, but a lower cut-off 
[< 100 μg/g] was needed to identify children with ‘deep healing’ [i.e., a combination of mucosal and 
transmural healing].30  
Practical guidance  
Repeat faecal calprotectin measurements in patients in clinical remission [tight control] makes it 
possible to identify a disease flare early. Several studies have shown that an increase in faecal 
calprotectin precedes the recurrence of symptoms by 2 to 3 months.31 Nonetheless, pre-emptive 
treatment escalation based solely on faecal calprotectin results is currently not recommended. Both 
adult and paediatric studies have shown that the combination of faecal calprotectin with CRP is 
superior to faecal calprotectin alone. The landmark CALM trial on the treat-to-target strategy in adult 
CD showed that faecal calprotectin levels < 250 μg/g in combination with Crohn’s disease activity 
score [CDAI] < 150 and CRP < 5 mg/L can be used as a treatment target, with step-by-step dose 
escalation of adalimumab until these levels are reached.17 Using this strategy enhanced mucosal 
endoscopic healing compared to reliance on symptoms alone to guide treatment. In another adult 
study the combination of faecal calprotectin with CRP was superior in detecting endoscopic disease 
activity than using faecal calprotectin alone.32 This has also been shown in the paediatric ImageKids 
and comparator cohorts while developing the MINI [Mucosal Inflammation Noninvasive Index]33. This 
composite score was statistically more accurate in detecting endoscopic healing than faecal 
calprotectin alone, albeit with a modest clinical benefit.  
Unlike endoscopic assessment, periodic measuring of faecal calprotectin and CRP is feasible also in 
children. Calprotectin monitoring has clinical benefit particularly in teenage patients, who tend to 
under-report complaints, and in those who have irritable bowel syndrome in addition to IBD.34 To 
minimise misinterpretation of calprotectin changes over time it is prudent to use calprotectin assays 
from the same manufacturer.35  
 
5.2 Small bowel imaging: magnetic resonance enterography [MRE] and intestinal ultrasound [IUS] 
ECCO-ESPGHAN statement 4  
In patients with luminal CD, assessment of transmural involvement by bowel ultrasound or magnetic 
resonance imaging can be used as a marker of treatment response.  
LoE: 3 | Agreement: 100% 
 
Evidence  
Cross-sectional imaging techniques, including MRE and intestinal ultrasound [IUS], can be used to 
periodically evaluate the effect of therapy on the bowel wall.36 MRE is currently the modality of 
choice to evaluate small-bowel involvement.37,38 In a recently published diagnostic meta-analysis, the 
sensitivity and specificity of MRE to identify active CD in children was 83% (95% confidence interval 
[CI]: 75%–89%) and 93% (95% CI: 90%–95%), respectively.39  
Active inflammation is best described by features that include wall enhancement, mucosal ulcers, 
and wall T2 hyperintensity, while damage is best recognised by the presence of a fibrotic stricture, 
abscess, or fistula.40  
Both MRE and IUS are non-invasive imaging techniques without ionising radiation; IUS has the 
additional advantages of low costs and easier access. The downside is that the interpretation of IUS 
strongly depends on the operator’s skills and experience.41 Among the features that can be evaluated 
during IUS, parietal thickness < 3 mm better predicts transmural healing than colour Doppler grade 
and the percent increase of parietal enhancement.42 In a prospective paediatric study comparing the 
diagnostic performance of MRE, IUS, and capsule endoscopy to assess small-bowel activity, no 
significant differences in the accuracy of the three imaging modalities were reported.43  
Practical guidance  
Adequate bowel preparation is required for MRE to promote good intestinal loop distention. 
Cooperative children may be able to drink sufficient volumes of oral contrast, while others require 
temporary placement of a nasojejunal tube for administration. Many centres now use a small-
volume lactulose protocol that has significantly improved compliance.44 MRE can be completed 
without sedation in the majority of children ≥ 9 years,45 while for young children sedation or general 
anaesthesia is likely to be required.46  There have been recent reports of gadolinium deposits in the 
human body, particularly in the brain, especially after repeated intravenous administration.47 The use 
of gadolinium-based MRI contrast agents should therefore be carefully individualised, especially 
when future repetition of small-bowel imaging is anticipated.  
 
  
5.3 Clinical disease activity scores 
ECCO-ESPGHAN statement 5 
In patients with luminal CD, clinical scores alone [PCDAI, wPCDAI, shPCDAI, abbrPCDAI] do not 
adequately reflect mucosal healing.  
LoE: 3 | Agreement: 100% 
 
Evidence  
Clinical disease activity scores are not accurate in assessing mucosal inflammation, as found both for 
the CDAI in adults48 and for the various versions of the PCDAI in children.21,49 Approximately half of 
patients in clinical remission will still have residual mucosal ulceration. Therefore, although the 
weighted PCDAI has better diagnostic accuracy for clinical remission compared to the other PCDAI 
versions,49,50 if MH is the treatment target, clinical assessment alone is insufficient for assessing 
therapeutic effect.  
Practical guidance 
A composite score of faecal calprotectin, CRP and clinical score is currently considered to be the best 
suitable non-invasive test to evaluate MH in paediatric CD.  
 
6. INDUCTION THERAPY IN LUMINAL CD 
6.1 Exclusive enteral nutrition 
ECCO-ESPGHAN statement 6  
In children with active luminal CD, dietary therapy with exclusive enteral nutrition [EEN] is 
recommended as first line for induction of remission.  




EEN involves the use of a complete liquid formula as the sole source of food for 6 to 8 weeks. Several 
meta-analyses have compared the efficacy of EEN with corticosteroid induction therapy in paediatric 
patients with luminal CD and concluded that there was no statistical difference in clinical remission in 
the intention-to-treat analysis.51,52 When only those patients who completed the treatment originally 
allocated were compared [per-protocol analysis], a slightly [but statistically significant] larger 
proportion of patients on EEN reached clinical remission.52 However, patients on EEN were more 
likely to withdraw from the allocated treatment than those on corticosteroid therapy. The most 
common reason for withdrawal included unpalatable formulations and poor acceptance of a 
nasogastric tube. Frequently reported side effects by patients on EEN included diarrhoea and 
vomiting. In paediatric CD patients with an extended period of nutrition deprivation, reintroduction 
of calories may lead to refeeding syndrome.53  
An Italian RCT that was included in two meta-analyses failed to show a significant difference in 
clinical remission rates between EEN and corticosteroid therapy. However, a significant difference in 
mucosal healing in favour of EEN was observed.54 These findings were recently replicated in a French 
RCT that included 19 children with CD and demonstrated a 89% mucosal healing rate with EEN 
compared to 17% upon induction therapy with corticosteroids.55  
When asked, patients would have a preference for a solid food based dietary induction rather than 
liquid diet.56 Until recently, more palatable and sustainable dietary strategies with similar efficacy to 
EEN were not available. Recently, several more tolerable food-based diets were introduced, including 
CD-TREAT57 and the Crohn’s Disease Exclusion Diet [CDED].58 In a head-to-head RCT, paediatric CD 
patients tolerated the CDED coupled with partial enteral nutrition [PEN] better than EEN and a larger 
proportion had sustained clinical remission at week 12.58 Replication studies, including data on 
mucosal healing, are required before strong recommendations can be made.  
  
Practical guidance 
Paediatric CD patients with purely inflammatory disease behaviour [B1] and low-to-medium risk at 
diagnosis [see Table 1] are eligible for EEN; this choice can be independent of disease location. There 
is no difference in efficacy between the elemental and non-elemental formula, or between diets of 
similar protein composition with different fat composition, or between bolus oral feeding and 
continuous enteral feeding.51,59 Considering the reduced palatability, the risk of early withdrawal, and 
the high costs associated with elemental diets, the primary choice being a polymeric formula is 
justifiable. Use of a nasogastric feeding tube may be considered to overcome aversion to the formula 
or not achieving the required daily intake. Food-based diets may be alternatives for patients who 
cannot tolerate EEN. 
 
6.2 Corticosteroids 
ECCO-ESPGHAN statement 7  
In children with active luminal CD, when EEN is not an option, corticosteroids may be considered for 
inducing remission.  
LoE: 3 | Agreement: 94% 
 
Evidence 
If EEN is poorly tolerated or is ineffective after 2 to 4 weeks of good compliance, systemic 
corticosteroids may be considered for inducing remission. Although corticosteroids have been used 
for decades to induce clinical remission in CD, surprisingly little evidence exists for their use in 
children.60-62 Corticosteroid use varies greatly between centres and countries and possibly depends 
on local expertise, bias, and health economic arguments.63,64 Corticosteroid use has been associated 
with increased risk of infection and elevated risk of intra-abdominal or pelvic abscesses,65,66 but when 
asked, the side effect of most importance to users are weight gain, insomnia, and Cushingoid facies.67  
  
Practical guidance 
The prednisolone starting dose is weight-dependent [see Table 2] and should be tapered once clinical 
remission is reached, but not later than 4 weeks after initiation. In the case of mild ileocaecal disease 
[L1], if EEN is insufficiently effective, treatment with ileal-release budesonide is preferable to 
prednisolone. For patients > 40 kg, the initial dose of budesonide is 9 mg once daily for 6 weeks and 
then tapered as follows: 6 mg once daily for 2 weeks, 3 mg once daily for 2 weeks. Doses up to 12 mg 
have been used for the first 4 weeks.68 There is no evidence of benefit for budesonide in more distal 
colonic inflammation. The likelihood of adverse events with budesonide is lower than with 
conventional corticosteroids.69  
Patients who require major surgery while taking supraphysiologic doses [> 50% of prednisolone 
starting dose; Table 2] for three weeks or more should be assumed to have adrenal insufficiency [AI] 
and will need additional peri-operative hydrocortisone coverage. Patients with unclear adrenal 
suppression [i.e. those who are in the last few weeks of their tapering scheme or those who finished 
corticosteroid therapy in the past 3 months] should be considered for endocrinologist counselling 
and preoperative hypothalamic–pituitary–adrenal axis testing.70,71  
 
6.3 Anti-TNF therapy 
ECCO-ESPGHAN statement 8  
In new-onset patients with high risk for a complicated disease course, anti-TNF therapy is 
recommended for inducing remission.  




Of all licensed drug therapies, anti-TNF agents [e.g., infliximab and adalimumab] are highly effective 
to induce both clinical and endoscopic remission and therefore have had a significant impact on the 
care of paediatric patients since their registration studies.72,73 A propensity-score matched analysis of 
the RISK study suggested that early anti-TNF monotherapy [within < 3 months after diagnosis] had 
higher corticosteroid- and surgery-free remission rates at 1 year than induction with EEN or 
corticosteroids followed by immunomodulator therapy.74  
As discussed in section 4 in connection with risk stratification, early treatment with anti-TNF agents 
was associated with a significantly lower risk of developing penetrating [B3] complications but did 
not seem to reduce the risk for stricturing [B2] complications.6 Comparison of top-down [first-line 
infliximab; discontinuation when endoscopic remission was reached after 1 year] with step-up 
treatment in a South Korean cohort [n = 76] found that deep remission and mucosal healing rates 
were higher in the top-down group.75,76 Although promising, these studies are limited by the non-
randomised trial design and relatively short follow up. The TISKIDS trial77 has now been reported in 
abstract form and is the first head-to-head comparison of top-down infliximab and first-line EEN or 
corticosteroids in children with moderate to severe CD.78 At 52 weeks, the primary end-point of 
clinical remission [wPCDAI <12.5 points without need for treatment escalation] was achieved in 41% 
on top-down infliximab versus 12% on conservative treatment (p=0.002). These data provide support 
for infliximab as first-line treatment option, albeit the regimen used in the TISKIDS trial 
[discontinuation of infliximab after five infusions] is outdated and no longer advised. The panellists 
recommend anti-TNF therapy as primary induction and maintenance therapy in children with a high 
risk of poor outcomes [see Table 1]. Anti-TNF agents should be considered early in the treatment 
plan in patients with severe growth delay or in those who do not reach clinical [PCDAI < 10] and 
biochemical remission [faecal calprotectin < 250 μg/g] after induction with EEN or corticosteroids.  
Practical guidance 
Intravenous administration of infliximab is usually at 5 mg/kg with three induction doses over 6 
weeks [week 0-2-6], followed by maintenance therapy of 5 mg/kg every 8 weeks. However, there is 
ample evidence79 that children < 30 kg and those with extensive disease and low serum albumin 
levels require higher induction doses up to 10 mg/kg, shorter dosing intervals, or both to reach target 
trough levels [see section 9.2].  
Adalimumab is administered subcutaneously. For patients > 40 kg the first induction dose is 160 mg, 
followed by 80 mg at week 2, and then followed by a maintenance dose of 40 mg every other week. 
For patients < 40 kg the drug label recommends 80 mg at week 0 and 40 mg at week 2 and 20 mg 
from week 4 onwards, but in view of the evidence on underdosing of young children higher doses 
may be required in specific cases. Weekly injections should be considered in patients losing response 
or with low trough levels [see section 9.2]. 
 
ECCO-ESPGHAN statement 9  
In patients with active CD who fail to achieve or maintain remission with an immunomodulator, anti-
TNF agents are recommended for induction and maintenance of remission.  
LoE: 2 | Agreement: 96% 
 
Evidence 
The median disease duration in paediatric patients who participated in the initial infliximab and 
adalimumab RCTs [REACH and IMAgINE, respectively]72,73 was approximately 2 years. They were 
eligible when they had active CD [i.e., PCDAI > 30] despite corticosteroids and immunomodulator 
use. Accordingly, the evidence of efficacy of anti-TNF agents in this category of patients is stronger 
than in any other patient category.  
The REACH study included 112 children with CD who received a standard infliximab induction and 
then one of two maintenance schedules every 8 or 12 weeks. At 54 weeks, remission rates were 56% 
versus 23.5%, respectively.72 In an open-label extension study, 80% of those who initially responded 
had at most mild disease at last follow up.80 The IMAgINE study provided weight-based induction 
with adalimumab and then randomised patients to high- versus low-dose weight-based 
maintenance. Similar remission rates were observed at 26 weeks [39% and 29%, respectively; NS].73 
More recent ‘real-life’, retrospective, or registry studies suggest higher remission and durability rates 
than those reported in the original RCTs. For example, high durability was shown for 180 patients 
receiving infliximab for CD, where 86% remained on this therapy for a median of 86 weeks. However,  
57% required dose escalation.81 This reflects the need for paediatric-specific dosing and drug 




Although thalidomide use to induce remission in CD has some support, a systematic review of 12 
thalidomide studies [2 RCTs, 10 case series] found only one study of sufficient methodological 
quality.82 In this paediatric RCT, the effect of thalidomide versus placebo was evaluated in patients 
with active CD refractory to immunosuppressive medications.83 Thalidomide was effective for the 
induction of remission in paediatric CD, and in a follow-up study the majority of patients who 
reached clinical remission had endoscopic and histological healing at 12 months.84 Further evidence 
is needed to confirm the generalisability of these findings. 
 
Practical guidance  
Due to the numerous potential side effects, such as sedation [32%] and peripheral neuropathy [20%], 
and its teratogenicity, thalidomide as induction therapy is restricted to a very selected cohort of 
paediatric CD patients, such as those who are intolerant to parenterally administered therapies 
despite psychological support or those refractory to several biologics. Thalidomide starting doses of 
50 mg daily orally are usually administered in adult patients and then subsequently increased 
according to response and tolerance; this seems appropriate also for adolescents with CD. Reduced 
doses should be considered for young children. Pregnancy testing must be performed in young 
women with CD prior to starting and while on thalidomide. Contraception is mandatory in young 
women with CD starting thalidomide if there is any likelihood of sexual activity.  
  
6.5 Thiopurines 
ECCO-ESPGHAN statement 10  
In children with active CD, thiopurine monotherapy should not be used to induce remission.  
LoE: 4 | Agreement: 100% 
 
Evidence  
The effectiveness of thiopurines to induce remission in adult CD has been summarised in a Cochrane 
systematic review and meta-analysis of five placebo-controlled RCTs [small numbers, some 
methodological issues present] on 380 patients. Thiopurines were no more effective than placebo in 
inducing remission [RR: 0.87; 95% CI: 0.71–1.06], with remission rates of 48% and 37%, 
respectively.85 The evidence base is weak in paediatric CD, with merely extrapolated evidence if the 
thiopurine was started at the same time as corticosteroids to induce remission.  
 
7. INDUCTION THERAPY IN FISTULISING PERIANAL CD 
ECCO-ESPGHAN statement 11  
In patients with fistulising perianal disease, anti-TNF therapy is recommended as the primary 
induction and maintenance therapy, in combination with antibiotic therapy, surgical treatment, or 
both.  
LoE: 3 | Agreement: 100% 
 
Evidence 
Within the group of perianal abnormalities in CD, non-fistulising and fistulising lesions can be seen. 
The non-fistulising lesions, including fissures and skin tags, will improve on medical treatment alone. 
On the other hand, fistulising lesions [abscesses and fistulas] may require potent medical and surgical 
intervention. The various surgical techniques are described in two recently published consensus 
guidelines on surgery for CD.86,87 Currently, the most efficacious treatment for fistulising perianal 
disease is anti-TNF therapy.88,89 Before anti-TNF therapy is initiated, symptomatic fistulas require 
collections to be drained using loose non-cutting setons. This allows the inflammation around the 
tract to subside and prevents abscess recurrence. 
Antibiotics [ciprofloxacin or metronidazole] can be used as an adjuvant, but not as a sole treatment. 
Patients treated with both ciprofloxacin and anti-TNF agents had better outcomes than anti-TNF 
agents alone.90 In complex fistulas, anti-TNF failure is common with a risk for the need of a diverting 
ostomy.91-93  
Practical guidance  
The usual daily doses for metronidazole are 30 mg/kg/day orally in two to three divided doses, and 
for ciprofloxacin 20 mg/kg/day orally in two divided doses. If healing is not optimal, anti-TNF dosing 
should be adjusted guided by trough level measurements [see section 9.2 on the optimisation of 
anti-TNF therapy] before changing to another therapy. Higher infliximab doses may be beneficial for 
perianal fistulising disease, with target trough levels > 12.7 μg/mL associated with better response.94 
Ustekinumab may be attempted in children and adolescents with active perianal fistulising disease 
refractory to anti-TNF agents, but the quality of evidence for a significant effect for this indication in 
adults is low and data are sparse.95-97 In a large adult cohort with active perianal Crohn’s disease the 
success rate of vedolizumab was low.98  
 
8. MAINTENANCE THERAPY 
8.1 Methotrexate 
ECCO-ESPGHAN statement 12  
Methotrexate can be used to maintain clinical remission as a first-choice immunomodulator, or after 
thiopurine failure or intolerance.  




The effectiveness of methotrexate to maintain remission in adult CD has been summarised in a 
Cochrane review of five RCTs involving 333 patients. Weekly intramuscular or subcutaneous [SC] 
administration of 15 mg methotrexate was significantly more effective than placebo in maintaining 
clinical remission [RR: 1.67; 95% CI: 1.05–2.67], whereas low-dose oral methotrexate [12.5 mg] was 
not more effective than placebo.99  
The evidence base is weaker in paediatric CD; there are no RCTs and almost all publications are on 
methotrexate use after thiopurine failure or intolerance. A systematic review of six observational 
studies of methotrexate use to maintain remission in 409 paediatric CD patients evaluated three 
retrospective cohort studies of 314 patients by meta-analysis and revealed a pooled maintenance 
clinical remission rate of 37.1% [95% CI: 29.5%–45.5%] at 12 months.100 A systematic review without 
meta-analysis of 10 observational studies [using less rigorous exclusion criteria for studies] showed a 
maintenance clinical remission rate of 25%–53% at 12 months and with mean durations of remission 
of 21–24 months.101 In terms of safety, adverse events most often included nausea and vomiting, 
elevated liver function tests, headache, infections, and haematological toxicity.101 A systematic 
review of hepatotoxicity in paediatric IBD patients on methotrexate revealed abnormal liver 
biochemistry in 10% and drug discontinuation due to hepatotoxicity in 5%.102  
The only head-to-head comparison of methotrexate and azathioprine was in a small RCT of 54 adult 
CD patients with chronic active disease randomised [after induction with prednisolone for at least 12 
weeks] to receive methotrexate or azathioprine for a 6-month period. The quality of evidence was 
very low due to multiple methodological concerns and there were no differences observed with 
respect to remission rate after 3 [methotrexate 44%, azathioprine 33%; p = 0.28] and 6 
[methotrexate 56%, azathioprine 63%; p = 0.39] months, respectively.103 Paediatric CD studies have 
all been observational, with 11 retrospective cohort studies or case series reporting on the 
sequential use of methotrexate after thiopurine failure [non-response, loss of response, intolerance, 
or non-adherence].104-114 In contrast, there have been no studies reporting on the sequential use of 
thiopurine after methotrexate failure. The change in immunomodulator practice in North America 
has however been driven by concerns around relative safety rather than relative effectiveness.  
Practical guidance  
Intramuscular and SC routes have similar pharmacokinetics; however, self-injecting via a SC route 
may be easier and better tolerated by patients. Accordingly, methotrexate is usually administered in 
practice SC once weekly at a dose of 15 mg/m2 [body surface area] to a maximum dose of 25 mg. If 
sustained clinical remission with mucosal healing is achieved, an attempt can be made to decrease 
the dose to 10 mg/m2 once a week to a maximum of 15 mg. No therapeutic drug monitoring [TDM] is 
available for methotrexate. Oral administration of folate [5 mg 24–72 h after methotrexate once 
weekly or 1 mg once daily for 5 days per week] is advised to reduce hepatotoxicity and 
gastrointestinal side-effects.115 There were no differences between oral and SC groups in terms of 
sustained corticosteroid-free remission at 12 months in a retrospective cohort study with propensity 
scoring for sub-group [mode of methotrexate administration] analyses of 226 paediatric CD patients 
and no differences in need for treatment escalation or adverse effects.104 Many centres will switch 
from SC to oral methotrexate once effectiveness has been demonstrated by 4 months. This obviates 
potentially painful injections and is more convenient, less expensive, and has no evidence of more 
adverse effects. The option exists to switch back to the SC route due to lost effectiveness or 
intolerance.101,111  
Nausea and vomiting are major problems both at start of methotrexate therapy and during 
maintenance use; administration of ondansetron 1 hour prior to dosing and for 1 [occasionally more] 
days afterwards from the outset may reduce nausea and improve tolerance.116 Methotrexate is 
teratogenic and is strictly contraindicated in pregnancy; an effective birth control method [if 




ECCO-ESPGHAN statement 13  
In patients who have reached remission, thiopurines [azathioprine or 6-mercaptopurine] can be used 
to maintain remission.  
LoE: 3 | Agreement: 88% 
 
Evidence  
The effectiveness of thiopurines [azathioprine or 6-mercaptopurine] to maintain remission in adult 
CD has been summarised in a Cochrane review of six RCT with 489 patients. Azathioprine was 
significantly more effective than placebo in maintaining steroid-free remission in CD [RR: 1.19; 95% 
CI 1.05–1.34], giving a number needed to treat for additional beneficial outcome of 9.117 At the same 
time, azathioprine users had a significantly greater risk of adverse events, such as pancreatitis, 
leukopenia, nausea, and infection [RR: 1.29; 95% CI: 1.02–1.64] and serious adverse events [RR: 2.45; 
95% CI: 1.22–4.90]. 
The evidence in paediatric CD is weaker, with just one small RCT of early use of 6-mercaptopurine 
that had several methodological limitations. This study showed a shorter duration of steroid use in 6-
mercaptopurine versus placebo, lower cumulative steroid dose at 6, 12, and 18 months, and lower 
relapse rate [9% vs 47%; p = 0.007].62  The remaining published studies were observational and 
reported 12-months corticosteroid-free remission rates of 23 to 60%.74,118-122 
Practical guidance  
The maximum effectiveness of thiopurines may require 8–16 weeks. The recommended azathioprine 
dose is 2.0–2.5 mg/kg and 1.0–1.5 mg/kg once daily for its prodrug, 6-mercaptopurine. The full 
thiopurine dose may be prescribed from the outset without the need for gradual dose increase. 
Haematological toxicity occurs in 2%–14% of cases, typically in the first months of treatment. 
Pancreatitis develops in up to 7% of patients, is usually idiosyncratic, occurs within the first weeks 
after treatment initiation, and typically requires cessation of the drug.123 Increased transaminases up 
to twice the upper limit of normal may be transient or resolve after drug tapering or discontinuation. 
If newly raised transaminases are observed, treatment should be discontinued and thiopurine 
metabolites should be assessed, if available. Thiopurines should be withheld until transaminases are 
in the normal range again; if unresolved, further investigations for liver disease should be performed. 
In patients with nausea and vomiting due to azathioprine therapy, interventions include split dosing, 
switch to 6-mercaptopurine, and use of low-dose thiopurine in combination with allopurinol [see 
8.2.2]. 
 
8.2.1 Pre-treatment genotyping 
Variants in the gene encoding thiopurine S-methyltransferase [TPMT] alter its enzymatic activity. 
Patients with low or absent TPMT activity are at an increased risk of developing severe, life 
threatening myelotoxicity from thiopurines if conventional doses are given. Three RCTs that included 
more than 1100 IBD patients did not demonstrate clinical benefit of TPMT gene testing prior to drug 
initiation, but up-front thiopurine dose reduction in those with heterozygosity led to an 89% risk 
reduction of haematologic adverse drug reactions.124-126 In addition to considering testing for TPMT 
gene variants prior to initiation of thiopurines, testing for NUDT15 variants can also be considered, 
particularly in patients of Asian origin.127,128 Pre-treatment genotyping does not replace haematologic 
safety monitoring, but could be considered as an addition to optimise thiopurine treatment. CD 
patients initiating thiopurine therapy should have baseline complete blood counts and liver enzymes 
measurements. Close blood and liver monitoring should be performed monthly in the first 3 months 
and then at least once every 3 months thereafter. Thiopurine dose reduction is required in patients 
who are heterozygous for TPMT or with intermediate enzymatic activity.  
 
8.2.2 Thiopurine metabolite testing 
In patients on thiopurine maintenance therapy, determining metabolite levels (6-thioguanine 
nucleotides [6-TGN] and 6-methylmercaptopurine [6-MMP]) with TDM can guide management. 
Metabolite testing is helpful in patients with suboptimal response, for evaluation of cytopenia or 
elevated liver enzymes, for monitoring compliance, and for optimising drug dosing. Desired ranges 
are shown in Table 3. In children with suboptimal 6-TGN levels and high 6-MMP values, addition of 
allopurinol can be considered at 50 mg once daily with thiopurine dose reduced to 25%–33% of 
original; this will harmonise metabolite levels and increase corticosteroid-free remission rates.129-131  
 
8.2.3 Thiopurines and cancer risk 
The absolute risk of malignancy in IBD patients treated with thiopurines is small but cannot be 
neglected. The main risk identified in different studies of IBD patients treated with thiopurines is for 
developing lymphomas (including the extremely rare but devastating hepatosplenic T-cell lymphoma 
[HSTCL] which occurs predominantly in young males) and non-melanoma skin cancers. In the 
CESAME trial that included 19,486 adult IBD patients, the multivariate-adjusted hazard ratio [HR] of 
lymphoproliferative disorders between patients receiving thiopurines and those who had never 
received these drugs was 5.28 [95% CI: 2.01–13.9].132 Another meta-analysis revealed a pooled 
standard incidence ratio for lymphoma of 4.92 [95% CI: 3.10–7.78] for thiopurine-exposed patients, 
especially in young men.133 Importantly, the increased risk does not appear to persist after 
discontinuation of therapy. Finally, in a nationwide French cohort of 189,289 IBD patients, the risk of 
lymphoma was higher among those exposed to thiopurine monotherapy [adjusted HR: 2.60; 95% CI: 
1.96–3.44], was equivalent to anti-TNF monotherapy [adjusted HR; 2.41, 95% CI: 1.60–3.64], and was 
higher for those on combination therapy with anti-TNF agents [adjusted HR 6.11; 95% CI: 3.46–10.8]. 
However, the absolute incidence rate was low.134 In a prospective survey of paediatric IBD patients in 
25 countries over 42 months, 20 of 21 cases with a hematopoietic malignancy were exposed to 
thiopurines, and 15 were exposed in the last 3 months prior to diagnosis.135 These findings support 
the observations made in 5,766 participants in another prospective registry of long-term outcomes 
of paediatric IBD patients. Thirteen of 15 patients who developed a malignancy and all 5 patients 
who developed haemophagocytic lymphohistiocytosis [HLH] had been exposed to thiopurines; 10 
patients with malignancy had also been exposed to a biologic agent.136 Risk factors for the 
development of HSTCL include male gender, age < 35 years, and at least 2 years of thiopurine 
exposure.137 All patients started on thiopurines, alone or in combination with biologic agents, should 
be counselled on the risk of lymphoma, though the absolute risk increase is extremely low. There are 
concerns that a primary infection with Epstein-Barr virus (EBV) during thiopurine therapy increases 
the risk for HLH and lymphoma.138 In a consensus guideline on the management of opportunistic 
infections in patients with IBD, ECCO recommended knowing the EBV serological status before 
beginning immunomodulatory treatment,139 but routine testing has not been widely accepted in 
paediatric practice.140  
The benefits of long-term immunosuppressive regimens should be considered on an individual 
patient basis. To date, no such risk has been detected with low-dose once weekly methotrexate as 
concomitant immunomodulator, a strategy that has been endorsed by other recent paediatric 
clinical practice guidelines.141 
Given the non-melanoma skin cancer risk, especially after several years of therapy, patients should 
be monitored routinely in clinic, including dermatologic evaluation, and use sun protection 
measures.142  
 
8.3 Maintenance enteral nutrition 
ECCO-ESPGHAN statement 14  
In children with low-risk CD who achieved clinical remission, monotherapy with maintenance enteral 
nutrition [at least 50% of daily energy requirements] can prolong remission.  
LoE: 3 | Agreement: 87% 
 
Evidence 
Maintenance enteral nutrition [MEN] refers to a proportion of diet provided by proprietary formula 
that is specifically used to reduce the risk of subsequent relapse after successful induction treatment, 
usually by EEN. MEN and PEN are terms often used interchangeably in the literature, but in this 
guideline MEN will be used. The evidence for the clinical efficacy of MEN comes from RCTs [small 
numbers, methodological issues present] predominately performed in Japanese adults with CD. In a 
clinical trial in adult CD, for patients randomised to thiopurines or MEN [50% of total energy 
requirements, i.e., > 900 kcal/day given as elemental formula], clinical relapse rates at 2 years were 
no different between the two groups and were significantly better than a third group with neither of 
these treatments.143 In addition, in two studies comparing MEN for 1 year to free diet, the MEN-
treated patients had lower endoscopic disease activity, lower mucosal inflammatory cytokine levels, 
and a significant reduction in relapse.144,145 The same feeding regimen was also associated with a 
reduced risk for postoperative recurrence after bowel resection for CD.146 A meta-analysis of three 
Japanese studies concluded that MEN in combination with infliximab was more effective in 
maintaining clinical remission after 1 year than infliximab monotherapy.147 Several retrospective 
paediatric studies using 20-50% of daily requirements have been performed, but an analysis of the 
reports suggests that the findings are inconsistent.23,148-152 Notwithstanding the low-quality evidence 
base, the panellists concluded that the desirable effects of adherence to MEN probably outweigh the 
undesirable effects and therefore made a conditional recommendation. 
Practical guidance 
Adherence with MEN in the medium term is poor; hence lack of effect may be partially due to poor 
adherence rather than lack of efficacy per se. MEN may work well as a short-term bridge between 
treatments [e.g., after EEN while waiting for immunosuppression to be fully effective, or as an 
adjunct to enhance the effect of other therapies, such as infliximab]. Despite elemental feeds being 
used in many studies, polymeric feeds as for EEN should be preferred for MEN, while an elemental 
diet is usually only indicated in the case of allergy to cow’s milk protein.  
 
  
8.4 Maintenance therapy after surgical resection 
ECCO-ESPGHAN statement 15  
Following ileocaecal resection, patients should be monitored by endoscopy 6–12 months post-
resection. In patients with high risk of recurrence, we recommend postoperative use of anti-TNF 
agents.  




Surgical resection in children with CD is usually reserved for those who are refractory to anti-TNF 
therapy, have stricturing [B2] disease with pre-stenotic dilatation, or penetrating [B3] disease. For 
most patients, surgery is not curative. Postoperative disease recurrence is common, but the risk can 
be reduced by using prophylactic medical therapy. Support for the postoperative use of anti-TNF 
therapy to reduce the risk of recurrence at the anastomosis comes from three RCTs conducted in 
adult patients with ileocolonic resections and primary anastomoses.153-155 
In a proof-of-concept study from Pittsburgh [USA], 24 patients were randomly assigned to receive 
infliximab, administered within 4 weeks of surgery and continued for 1 year, or placebo. Indications 
for surgery included small-bowel obstruction [n = 2] and penetrating complications related to intra-
abdominal abscess formation [n = 22]. The rate of endoscopic recurrence at 1 year was dramatically 
lower in the infliximab-treated group [9% vs. 85%; p = 0.0006].153 These findings paved the way for an 
international, multicentre, placebo-controlled RCT among 297 patients. At 18 months post-resection, 
a significantly smaller proportion of patients in the infliximab-treated group had endoscopic 
recurrence compared to the placebo group [30.6% vs 60.0%; p < 0.001].154 
The multicentre POCER study provided evidence that early colonoscopy 6 months postoperatively 
followed by treatment escalation in case of endoscopic recurrence was superior in preventing 
endoscopic recurrence at 18 months compared to standard care [i.e. no colonoscopy].156 In a 
secondary study among a subset of patients at high risk for disease recurrence, immediate and 
continuous postoperative treatment with adalimumab 40 mg every other week was superior to 
immediate and continuous daily thiopurine in preventing endoscopic recurrence at 6 months [21% 
vs. 45%; p = 0.028].155  
Practical guidance  
Endoscopic recurrence is an early signal for clinical recurrence. Mucosal lesions are usually seen 
proximal to the ileocolonic anastomosis. The Rutgeerts score [Table 4] is used in both paediatric and 
adult CD to assess the severity of inflammation in the neo-terminal ileum.157,158 Higher scores predict 
a higher risk of clinical recurrence and should trigger treatment escalation. The Rutgeerts score is 
simple to perform but has not been validated in children. If the anastomosis is not within reach of 
endoscopic examination, then disease recurrence may be evaluated with non-invasive modalities 
such as capsule endoscopy, MRE, and IUS159 complemented with faecal calprotectin.158,160  
Most paediatric CD patients in real-world settings will receive maintenance therapy administered 
within 4 weeks from surgery. Anti-TNF naïve patients may use a thiopurine to reduce postoperative 
recurrence of disease activity. Endoscopic recurrence on thiopurine monotherapy should trigger a 
step-up to anti-TNF therapy. In patients who had been following anti-TNF therapy until shortly before 
the operation, continuation of the same medical therapy is advised, provided that no anti-drug 
antibodies were detected before. Infliximab and adalimumab are probably equally effective in 
reducing postoperative recurrence.161  
In patients with diarrhoea following ileal resection, a therapeutic trial of bile acid sequestrants [i.e., 
colestyramine or colesevelam] is appropriate, particularly when faecal calprotectin values are in the 
normal range and 7-hydroxycholestenone levels are elevated.  
 
  
9. OPTIMISATION OF ANTI-TNF THERAPY 
9.1 Combination therapy with an immunomodulator 
ECCO-ESPGHAN statement 16  
In patients starting with infliximab, we recommend combination therapy with an immunomodulator.  
LoE: 2 | Agreement: 96% 
 
Evidence 
Immunomodulators, including thiopurines and methotrexate, administered concomitantly with anti-
TNF agents, reduce the likelihood of anti-drug antibody [ADA] development. In the SONIC trial, a 
double-blind RCT that compared infliximab plus thiopurine versus infliximab alone in adults receiving 
steroid induction therapy, clinical remission rates at week 26 and endoscopic improvement were 
higher with combination therapy [57% vs 44%; p = 0.02].162 Trough concentrations of infliximab in 
serum were higher and prevalence of ADA was lower with combination therapy. Administration of 
infliximab, however, was given precisely at 5 mg/kg every 8 weeks without optimising drug exposure 
via TDM. Indeed, a post-hoc analysis found clinical remission and endoscopic healing rates to be 
higher in higher quartiles of infliximab trough levels, irrespective of whether this greater exposure 
was achieved with or without concomitant thiopurine use.163   
In the COMMIT trial, the combination of infliximab plus methotrexate was associated with a lower 
risk for ADA development [4% vs 20%; p = 0.01]. Combination therapy was also associated with a 
trend to higher median infliximab trough levels than infliximab monotherapy [6.35 µg/mL vs 3.75 
µg/mL; p = 0.08].164 The clinical efficacy of infliximab monotherapy and combination therapy with 
methotrexate were comparable in this adult trial, where all patients also received full-dose steroids 
at induction.   
Paediatric studies on combination versus monotherapy are limited to retrospective data and show a 
lower likelihood of secondary loss of response [LOR] due to ADA development165 and a greater 
likelihood of remaining on infliximab over time166,167 when infliximab was initiated in combination 
with an immunomodulator. One open-label, paediatric trial randomised patients to combination 
therapy for 54 weeks or to combination therapy for 26 weeks followed by 26 weeks of anti-TNF 
monotherapy.168  At the end of the first year, there was no significant benefit of prolonged 
combination therapy. An adult follow-up study came to the same conclusion at the end of a 2-year 
observation period, with no difference between the groups in the likelihood of changing infliximab 
dosing or need to discontinue infliximab.169 The benefits of continued immunomodulation should be 
balanced against the increased risk of adverse events including cancers and lymphoma [see section 
8.2.3].  
Practical guidance   
Either once weekly oral or SC methotrexate or daily oral thiopurines reduce the likelihood of ADA 
development and the associated secondary LOR. Therefore, patients with perianal disease, 
stricturing or penetrating behaviour, or severe growth retardation should be considered for up-front 
anti-TNF agents in combination with an immunomodulator. Lower thiopurine doses allowing 
achievement of 6-TGN levels around 125 pmol/8 × 108 RBCs may be sufficient to reduce the risk of 
anti-infliximab antibody development.170,171 Consideration should be given to stopping the 
concomitant immunomodulator after 6–12 months of combination therapy, provided that drug 
trough levels are well within the target range and treatment targets [e.g., endoscopic and transmural 
healing] are achieved. 
 
 
ECCO-ESPGHAN statement 17  
In patients naïve to anti-TNF agents, adalimumab monotherapy is an alternative to adalimumab 
combination therapy.  
LoE: 3 | Agreement: 85% 
 
Evidence 
In comparison with infliximab, there is less evidence to suggest concomitant immunomodulation 
when starting adalimumab. The open-label DIAMOND trial compared the efficacy of a combination of 
adalimumab plus azathioprine and adalimumab monotherapy.172 Adult patients all naive to 
immunomodulators and biologics at study baseline had similar clinical remission rates at 26 weeks, 
irrespective of combination therapy or adalimumab monotherapy [68% vs 72% respectively; p = 
0.63]. Six months after study baseline, the rate of endoscopic improvement was significantly higher 
with combination therapy, but not at 12 months.   
Post-hoc analyses of cohort data from RCTs in adults did not show a significant benefit with 
combination adalimumab and immunomodulator therapy [thiopurine or methotrexate] over 
adalimumab alone for induction (odds ratio [OR]: 0.88; 95% CI: 0.60–1.27) or maintenance of 
remission [OR: 0.88; 95% CI: 0.58–1.35].173 In a post-hoc analysis of the paediatric IMAgINE-1 RCT, in 
which over 60% of patients received concomitant thiopurine or methotrexate therapy along with 
adalimumab, there was no difference in remission rates between those who received a concomitant 
immunomodulator and those who did not [36% vs 30%].73,174  
Recently, in the PANTS cohort study of 1,610 patients [14% aged < 18 years] with active luminal 
disease starting their first anti-TNF biologic, the proportion of adalimumab-treated patients not in 
remission at week 54 was not different for those receiving a concomitant immunomodulator [64.2%; 
95% CI: 57.6–70.4] compared with those receiving monotherapy [69.8%; 95% CI: 63.1–75.9].175 
Nonetheless, the PANTS study confirmed that ADA development is also significantly reduced in 
adalimumab-treated patients on combination therapy but with a smaller effect size [HR: 3.21; 95% 
CI: 2.61–3.95].176  
Practical guidance 
The available evidence overall suggests that adalimumab monotherapy is appropriate when started 
as a first anti-TNF agent. Although the data concerning adalimumab specifically as a second anti-TNF 
agent are very limited, it seems prudent to employ a concomitant immunomodulator when starting 
adalimumab in patients previously sensitized to infliximab or in high-risk patients when used as 
primary anti-TNF agent. 
 
9.2 Therapeutic drug monitoring 
ECCO-ESPGHAN statement 18  
In patients on anti-TNF agents, early pro-active therapeutic drug monitoring [TDM] followed by dose-
optimisation is recommended.  
LoE: 2 | Agreement: 87.5% 
 
Evidence 
Anti-TNF agents are highly effective drugs for the treatment of paediatric CD, but 10%–30% of 
patients do not respond to induction therapy [i.e., primary non-responders] and approximately 50% 
of initial responders lose response at a later time [i.e. secondary LOR]. Both primary non-response 
and secondary LOR in anti-TNF treated patients commonly result from either low trough 
concentration or high ADA titre or both.177-182 
TDM involves measuring drug concentrations and interpreting these concentrations for adjusting 
further drug dosages to maintain drug concentrations within an optimal targeted therapeutic 
window. Measuring anti-TNF trough concentrations when LOR is observed is referred to as reactive 
TDM. This was shown to improve efficacy of adalimumab in adults.183 Several retrospective studies 
demonstrated that routine measurements of trough concentrations and ADA [i.e. proactive TDM] in 
adult patients with CD treated with infliximab184,185 and adalimumab186 led to better clinical 
outcomes. The recently published PAILOT trial, a paediatric RCT, convincingly showed that proactive 
TDM in children who initially responded to adalimumab induction resulted in higher clinical 
remission rates compared to those managed with reactive TDM [82% and 48%, respectively; p = 
0.002]. Moreover, calprotectin levels declined to the target range of < 150 g/g in a higher 
percentage of patients in the proactive TDM cohort versus the reactive TDM group [42% versus 
12.5%, p = 0.003].187 Proactive TDM consequently resulted in higher treatment intensification rates, 
mainly early in the course of treatment. These findings emphasise the importance of early TDM in 
children with CD treated with anti-TNF agents, particularly in view of pharmacokinetic data implying 
that most paediatric patients are underdosed.188 
Practical guidance 
Proactive TDM is of benefit when performed early in the course of treatment [post-induction]. We 
recommend that paediatric patients with CD treated with adalimumab have their first proactive TDM 
just before the third injection [i.e., 4 weeks after the first dose]. Patients treated with infliximab 
should have their first proactive TDM just before the fourth infusion [i.e., 14 weeks after the first 
dose]. Patients at risk for accelerated infliximab clearance during induction [i.e children < 30 kg, 
those with extensive disease and those with low serum albumin] may have their first proactive TDM 
at the second or third infusion.189 The aim is to achieve trough concentrations in the therapeutic 
range, as specified in the following section.  
 
ECCO-ESPGHAN statement 19  
In patients with active CD who are treated with anti-TNF agents, it is recommended to use TDM to 
guide treatment changes over empirically escalating dose or switching therapies.  




There is a positive association between higher trough concentrations and better response to anti-
TNF therapy in both adults190,191 and children.189,192 In patients with ongoing symptoms and a 
persistently increased calprotectin concentration at the end of infliximab induction therapy [i.e., 
around 14 weeks], the decision pathway will be based on the trough level measurement.193-195 
Results below the therapeutic threshold require dose-escalation, interval shortening, or both. These 
interventions were shown to improve treatment efficacy in adults196 and children197 while being cost-
effective at the same time.198 In patients with ongoing symptoms despite adequate drug levels, a 
switch to a different class of biologicals [Figure 2] or surgery is warranted.   
In patients in whom active luminal disease subsided on anti-TNF agents but faecal calprotectin 
increased significantly during maintenance treatment, TDM can help guide the therapeutic strategy 
most likely to recapture response.  
Practical guidance 
In patients who experience primary non-response to anti-TNF agents, drug trough level [and ADA 
titre, if available] should be measured at the end of induction [i.e. before the fourth infliximab 
infusion, or before the third adalimumab injection] and in patients with secondary LOR at the time of 
losing response. Treatment changes should be based on TDM results and the consequent 
stratification to immunogenic [presence of ADA], pharmacokinetic [low trough concentrations 
without ADA], and pharmacodynamic loss of response [adequate trough concentrations], as shown 
in Figure 2. Target trough levels for anti-TNF agents are presented in Figure 3. A minimal 
maintenance threshold of 5 µg/ml for infliximab and 7.5 µg/ml for adalimumab should be targeted 
for endoscopic healing.199 Specific phenotypes, in particular perianal fistulising disease, may require 
even higher drug exposure for fistula healing [≥ 12.7 µg/ml infliximab].94 
Patients with low ADA titres may restore response following dose escalation, addition of an 
immunomodulator, or both, whereas patients with high ADA titre should be switched in-class [from 
infliximab to adalimumab or vice versa]. Patients with low trough levels without ADA should have a 
dose increase, and patients with trough levels that are well in range should be switched to an out-of-
class biological. Infliximab and adalimumab therapy should generally not be abandoned unless drug 
concentrations are greater than 10 µg/ml.199  
 
  
10. BIOLOGICS AFTER ANTI-TNF FAILURE 
ECCO-ESPGHAN statement 20  
In patients who fail to achieve or maintain clinical remission on anti-TNF agents, despite anti-TNF 
dose optimisation and immunomodulator use, ustekinumab or vedolizumab can be considered.  




Ustekinumab, a monoclonal antibody targeting interleukin 12 and 23, has demonstrated efficacy for 
induction and maintenance of clinical remission in randomised placebo-controlled trials conducted in 
adult patients with active CD, including those who had previously failed or were unable to tolerate 
anti-TNF therapy.200-202 In the CERTIFI trial, response but not remission rate at week 6 was higher with 
ustekinumab than placebo.201 However, in the UNITI-1 trial among patients previously treated with 
anti-TNF agents, one intravenous infusion of ustekinumab at 6 mg/kg resulted in improved rates of 
both response [34%] and remission [21%] at week 8 compared with placebo [22% and 7%, 
respectively].200 In a substudy of UNITI-1 that examined endoscopic outcomes, mean change in SES-
CD at week 8 with ustekinumab [-2.3 points] was better than with placebo [+0.2 points].200 
In the UNITI-IM maintenance trial, which included both anti-TNF naïve patients and those with prior 
anti-TNF exposure, significantly more patients were in remission with ustekinumab 90 mg SC every 8 
weeks after 1 year of treatment compared with placebo [53% vs 36%]. However, in the subgroup of 
patients with prior anti-TNF failure, there were no significant differences in clinical remission rates 
between ustekinumab and placebo at 1 year.200 In a systematic review and meta-analysis of these 
trials involving in total 1947 adult patients, ustekinumab was significantly better than placebo for the 
outcome of inducing remission [RR: 0.91; 95% CI: 0.86–0.95].203  
Data on ustekinumab efficacy in paediatric CD are still limited. Dayan et al. retrospectively reviewed 
outcomes with ustekinumab therapy administered similarly to the UNITI trials in 52 patients with 
median age 16.8 years [IQR: 14, 18], 42 of whom had CD.  Steroid-free clinical remission was 
achieved in 40% at week 52.204 As observed in adult studies, higher remission rates were seen in 
biologic-naïve patients versus those with prior anti-TNF failure. Another multicentre retrospective 
study of 44 children, all previously exposed to anti-TNF agents, reported a 39% clinical remission rate 
at 12 months with SC ustekinumab induction and maintenance.205  
Practical guidance 
The first dose of ustekinumab is usually administered intravenously and is 6 mg/kg rounded to 130 
mg [maximum 520 mg]. SC dosing starts at week 8; adult patients receive a 90-mg injection. Children 
should receive a body surface area [BSA]-adjusted dose [considering a standard adult of 1.73 m2] 
every 8 weeks. Clinical benefit can be observed from 8 weeks following intravenous induction. The 
safety profile of ustekinumab in adult and in the limited paediatric studies is very good. Additional 
paediatric safety data come from a RCT and clinical experience among paediatric patients with 
psoriasis.206  The immunogenicity of ustekinumab is low, and, although not assessed in a prospective 
RCT, concomitant administration of an immunomodulator does not appear to influence efficacy or 




Vedolizumab is a gut-selective humanized monoclonal antibody targeting the α4β7 integrin that is 
effective in patients with IBD who are refractory or intolerant to systemic steroids, 
immunomodulators, or anti-TNF agents.207-211 Vedolizumab is effective in both CD and UC, but is 
likely more effective in UC.212 Of the 13 studies identified, six studies reported higher rates of clinical 
response in patients with UC,212-217 six reported no difference218-224, and one reported higher rates of 
clinical response in CD.225 Mucosal healing is observed in 6%–63% of CD patients who used 
vedolizumab,213,214,224,226-232 which is lower than in UC [33%–77%].213-215,224,228,230,233 Higher rates of 
clinical response are observed when vedolizumab is given as a first-line biologic treatment [i.e., no 
prior anti-TNF therapy].210,234,235  
Anti-drug antibody development is uncommon.236,237 Severe adverse events leading to 
discontinuation of treatment with vedolizumab are rare [5%–10%].210,211,237 Vedolizumab use is not 
associated with increased risk of opportunistic infections238-242 or malignancy.238,240-244  
Practical guidance 
In patients ≥ 40 kg, vedolizumab should be administered intravenously at 300 mg with three 
induction doses over 6 weeks [week 0-2-6], followed by maintenance therapy of 300 mg every 8 
weeks. No specific guidelines exist for paediatric dosing. Younger paediatric patients may require an 
individualized dose of 6 mg/kg up to a maximum of 300 mg, or a BSA-based dose [considering a 
standard adult of 1.73 m2]. Response to vedolizumab can take time [≥ 16 weeks]. Some centres 
prescribe oral corticosteroids as ‘bridging therapy’ while waiting for the effects of vedolizumab to 
manifest. Data from clinical trials and real-world evidence studies suggests that an exposure-efficacy 
relationship may exist for vedolizumab, but robust target vedolizumab trough levels are currently 
lacking.245 Dose intensification by shortening the vedolizumab infusion interval to every 4 weeks may 
restore responsiveness in patients with LOR.246  
 
11. MICROBIAL MANIPULATION 
11.1 Probiotics 
ECCO-ESPGHAN statement 21  
In patients with CD, probiotics should not be used to induce or maintain remission.  
LoE: 2 | Agreement: 100% 
 
Evidence  
In the only paediatric RCT available, Lactobacillus rhamnosus strain GG given in addition to standard 
maintenance therapy had numerically higher relapse rates compared to placebo, but no statistical 
significance was noted between the groups.247 Similarly, Cochrane reviews on probiotics for 
induction or maintenance of remission in adult CD patients248,249 and a more recent systematic 




In the only paediatric RCT, a combination of azithromycin and metronidazole for 8 weeks was more 
effective than metronidazole alone for induction of clinical remission at 8 weeks in mild-to-moderate 
CD [66% vs 39%; p = 0.025]. However, the primary outcome measure, defined as a decrease in PCDAI 
> 12.5 points, was not statistically different between groups [66% vs 45%; p = 0.07]. Faecal 
calprotectin declined significantly in the combination group but not in the metronidazole group. 
However, levels in both groups remained high at 8 weeks.251 
According to a recent Cochrane review in adults, the effect of antibiotics on both induction and 
maintenance of remission in CD is uncertain and adverse events were not increased with antibiotics 
compared to placebo.252 The effect of antimycobacterial therapy is not clear in CD patients due to the 
very low quality of evidence.253 
Practical guidance  
A combination of antibiotics may be considered for induction of remission in mild-to-moderate 
paediatric CD where nutritional therapy is not an option. Various antibiotics were used in adult 
studies, but in the previously mentioned paediatric RCT azithromycin 7.5 mg/kg [5 days/week for 4 
weeks, dropping to 3 days/week for the second 4 weeks] and metronidazole 20 mg/kg/day [for 8 
weeks] were used.251 In addition to bacterial infections complicating CD, antibiotics may also be 
considered when bacterial overgrowth is suspected and for perianal disease [see section 7]. 
 
  
11.3 Faecal microbiota transplantation 
ECCO-ESPGHAN statement 22  
In patients with CD, faecal microbiota transplantation should not be used to induce or maintain 
remission.  
LoE: 2 | Agreement: 100% 
 
Evidence  
No RCTs evaluating faecal microbiota transplantation [FMT] in CD were identified in a Cochrane 
review.254 In a recent systematic review including a case series of 94 children and adults with CD, 
FMT was associated with a short-term remission rate of 30% in total and 45% in children, but these 
findings should be interpreted with caution due to publication bias and heterogeneity.255 Only 20 
children were reported in these case series. 
 
12. CONCLUSION 
The aim of this ECCO-ESPGHAN guideline update is to guide the clinicians’ decisions with the best 
evidence available to achieve sustained remission and improve quality-of-life. Regular measurements 
of disease activity, timely drug interventions, monitoring the effect of treatment, and attention to 
the psychosocial aspects of CD are necessary to achieve these goals. It is up to every clinician to 
adapt these guidelines to local regulations and to the patient’s individual characteristics and needs.  
Both ECCO and ESPGHAN will disseminate these guidelines by educational activities [such as 
workshops, e-learning, and e-Guide] to ensure that they are integrated into clinical practice. The 
ECCO e-Guide will serve as a resource to examine how the statements can be implemented into daily 
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Additional risk factors Risk 
stratification 
Suggested induction therapy 
B1 Inflammatory  
(non-stricturing,  
non-penetrating) 
None Low  Exclusive enteral nutrition; 
corticosteroids 
B1 No clinical and biochemical 
remission 12 weeks after start 
induction therapy  
Medium Consider accelerated step-up to anti-
TNF therapy 
B1+G1 Growth delay Medium  Exclusive enteral nutrition; consider 
up-front anti-TNF therapy 
B1 
(L3+L4) 
Extensive disease* or  
deep colonic ulcers 
High Up-front anti-TNF therapy 
B1+p Perianal disease High  Up-front anti-TNF therapy in 
combination with antibiotic therapy,  
surgery, or both 
B2 Stricturing disease** None High  Up-front anti-TNF therapy 
  Prestenotic dilatation, 
obstructive signs or symptoms, 
or both 
High Bowel resection in combination with 
postoperative anti-TNF therapy 
B3 Penetrating disease***  High  Surgery in combination with 
postoperative anti-TNF therapy 
*  defined as pan-enteric inflammation (i.e., involvement of proximal small bowel, terminal ileum, and colon); 
**  defined as the occurrence of constant luminal narrowing demonstrated by radiologic or endoscopic examination; 
***  defined as the occurrence of bowel perforation, intra-abdominal fistulae, inflammatory masses and/or abscesses at 
any time in the course of the disease (not the result of surgical complications) 
 
  
Table 2 | Prednisone or prednisolone tapering scheme (once daily administration) 
 
 Body weight 
Week 10–20 kg 20–30 kg > 30 kg 
1–3 20 mg 30 mg 40 mg 
4 15 mg 25 mg 35 mg 
5 15 mg 20 mg 30 mg 
6 12.5 mg 15 mg 25 mg 
7 10 mg 15 mg 20 mg 
8 7.5 mg 10 mg 15 mg 
9 5 mg 10 mg 10 mg 
10 2.5 mg 5 mg 5 mg 
As tapering schemes are largely based on empiric recommendations rather than  
on clinical trials, large variability exists among physicians. Shortening each stage  
from 7 to 5 days or any other tapering modification may be considered individually. 
  












- Under-dosing or 
low compliance 
Increase compliance or 










treatment and thiopurine dose 
reduction to 25%–33% of 












Change drug category if 
homozygote, or reduce dose to 
half if heterozygote 
High High Myelosuppression 
and hepatotoxicity 
Overdosing Reduce dose and if clinically 
resistant, change drug category 
* The cut-off values given in this table are based on the method according to Lennard;256 higher cut-off values (therapeutic 
range of 6-TGN from 300 to 600 pmol/8×108 RBC) are necessary when analyses are based on the method of Dervieux and 
Boulieu.257   
 
  
Table 4 | Rutgeerts scoring system for endoscopic recurrence of Crohn’s Disease157 
Endoscopic 
remission 
i0 No lesions in neo-terminal ileum 
i1 ≤ 5 aphthous ulcers 
Endoscopic 
recurrence 
i2 > 5 aphthous ulcers with normal intervening mucosa, skip areas of larger 
lesions confined to ileocolonic anastomosis 
i3 Diffuse aphthous ileitis with diffusely inflamed mucosa 
i4 Diffuse inflammation with large ulcers, nodules and/or stenosis 
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FIGURES 
Figure 1 | Summary flowchart of medical management of paediatric luminal Crohn’s disease 
The numbers displayed in the boxes refer to the statements in this guideline 
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Figure 2 | Anti-TNF therapeutic drug monitoring 
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Figure 3 | Target trough levels for anti-TNF agents to achieve mucosal healing in luminal CD. 
At the end of induction [i.e., before the fourth infliximab infusion, or before the third adalimumab 
injection] the target trough level is ≥ 5 µg/ml for infliximab and ≥ 7.5 µg/ml for adalimumab. In 
patients at risk for accelerated infliximab clearance during induction, an infliximab concentration ≥ 25 
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